Questions about this study?
The HopeStage team will email you.
WithdrawnNCT00916201
Evaluation Study of New Compounds With Potential Use in Schizophrenia
Researchers are comparing intranasal Insulin, Cannabidiol CR and URB597 to find out how the approaches affect depression symptoms in healthy volunteers.
Medication studyAges 18–65Germany
Understand this study
What is this study about?
Researchers are comparing intranasal Insulin, Cannabidiol CR and URB597 to find out how the approaches affect depression symptoms in healthy volunteers.
Who could participate?
This study is for healthy volunteers. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Mannheim, GermanySee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 31, 2025
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Central Institute of Mental Health, Mannheim
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Germany
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00916201
- Official title
Show the full official title
Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.
Recruitment & locations
WithdrawnMannheim
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing intranasal Insulin, Cannabidiol CR and URB597 to find out how the approaches affect depression symptoms in healthy volunteers.
Who is behind this study?
The study sponsor is Central Institute of Mental Health, Mannheim, a research institute.
Does this study involve medication?
Yes. The study involves medication, including URB597, intranasal Insulin and Cannabidiol CR.
Who can participate?
This study is for healthy volunteers. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study